Welcome to our dedicated page for Salarius Pharmaceuticals news (Ticker: SLRX), a resource for investors and traders seeking the latest updates and insights on Salarius Pharmaceuticals stock.
The news feed for Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) captures the company’s transition as it integrates Decoy Therapeutics and pivots toward a peptide-conjugate antiviral and oncology platform. Press releases and regulatory announcements describe how Salarius, historically a clinical-stage biopharmaceutical company with oncology assets, completed a strategic merger with Decoy and is preparing to operate under the Decoy Therapeutics name and the Nasdaq ticker symbol DCOY.
Readers following SLRX news can expect updates on corporate transformation, including the planned and then confirmed changes to the corporate name and trading symbol, as well as details of the merger structure, preferred stock issuance and leadership changes documented in company communications and SEC filings. The news flow also highlights capital markets activity, such as underwritten public offerings of common stock and warrants, at-the-market issuances and efforts to regain and maintain compliance with Nasdaq listing standards, including reverse stock splits and panel monitoring.
Sector-specific coverage focuses on drug development and platform progress. Company announcements describe the IMP3ACT peptide-conjugate platform, pan‑coronavirus and broad-acting antiviral programs, and a peptide drug conjugate targeting GI cancers. News items also cover collaborations, notably with Texas Biomedical Research Institute for in vitro testing of peptide conjugate fusion inhibitors across influenza strains including H5N1 avian flu, and recognition from programs such as the Massachusetts Life Sciences Seed Fund, the Google AI startup program, the NVIDIA Inception program and BARDA’s BLUE KNIGHT initiative.
By monitoring this page, investors and observers can review historical and ongoing disclosures around SLRX’s oncology heritage, its integration with Decoy’s AI- and ML-enabled peptide-conjugate platform, financing transactions and interactions with the Nasdaq Capital Market, all drawn from company-issued news and related filings.
Salarius Pharmaceuticals (Nasdaq: SLRX) has announced plans to submit an Investigational New Drug (IND) application for SP-3164 in 2023 after successfully completing a pre-IND meeting with the FDA. SP-3164 is a next-generation targeted protein degrader aimed at treating hematological and solid tumors. This novel agent may effectively eliminate cancer-causing proteins. The FDA provided critical feedback aiding in the preparation for the IND submission and subsequent clinical trials. Salarius aims to leverage SP-3164 amidst its ongoing clinical programs in an evolving cancer treatment landscape.
Salarius Pharmaceuticals (Nasdaq: SLRX) announced a conference call scheduled for May 12, 2022, at 5:00 p.m. ET to discuss its financial results for the first quarter of 2022. Interested participants can join via phone or listen to the live webcast on the company's investor relations website. Salarius is focused on developing innovative cancer therapies, including seclidemstat, which is in clinical trials for conditions such as Ewing sarcoma. The product has received multiple designations from the FDA, emphasizing its potential in treating unmet medical needs.
Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) has announced a registered direct offering, securing approximately $2.3 million through the sale of 9,339,436 shares at $0.25 per share. The offering, facilitated by Ladenburg Thalmann & Co. Inc., is set to close around April 26, 2022 and aims to fund clinical and pre-clinical development and general corporate purposes. Additionally, unregistered warrants for 7,004,578 shares with an exercise price of $0.3399 will also be issued to investors.
On March 10, 2022, Salarius Pharmaceuticals (SLRX) reported key corporate events and financial results for 2021. The company expanded its cancer therapy pipeline by acquiring SP-3164, a targeted protein degrader aimed at treating hematologic and solid tumors. Salarius reported a net loss of $12.8 million for the year, with cash reserves totaling $29.2 million, expected to support operations through 2023. Upcoming updates on clinical trials for both SP-3164 and seclidemstat are anticipated, with optimism for growth in 2022 and beyond.
Salarius Pharmaceuticals (Nasdaq: SLRX) will host a conference call and audio webcast on March 10, 2022, at 5:00 p.m. ET to discuss its financial results for the year ended December 31, 2021. The call will provide insights into its clinical developments, including seclidemstat, a cancer therapy in Phase 1/2 trials for Ewing sarcoma. The company has secured Fast Track, Orphan Drug, and Rare Pediatric Disease Designations from the FDA for this indication. Interested participants can join via provided U.S. and international phone numbers.
Salarius Pharmaceuticals (Nasdaq: SLRX) announced that CEO David Arthur will present at the Diamond Equity Research Emerging Growth Invitational 2022 Virtual Conference on February 24, 2022, at 10:20 a.m. ET. The presentation will focus on the company’s progress, including the Phase 1/2 clinical trial of seclidemstat, aimed at treating sarcomas and pediatric cancers, and recent acquisitions in protein degradation assets like SP-3164. Investors can register for free to attend the conference, with a recording available post-event on the company’s website.
Salarius Pharmaceuticals (Nasdaq: SLRX) announced that CEO David Arthur will present at the BIO CEO & Investor Conference, February 14-17, 2022, in New York. The presentation will cover Salarius' recent achievements, including the acquisition of targeted protein degradation assets for new drug development and updates on the seclidemstat clinical program. Attendees will have access to on-demand content and can schedule one-on-one meetings with the management team. Salarius focuses on developing therapies for sarcomas and pediatric cancers, with its lead candidate seclidemstat currently in clinical trials.
Salarius Pharmaceuticals announces the appointment of Dr. Daniela Santiesteban as Director of their new targeted protein degradation program, focusing on SP-3164. This role follows Salarius' expansion into targeted protein degradation through the acquisition of SP-3164 from DeuteRx. Dr. Santiesteban will oversee SP-3164's clinical trials, expected to file an IND with the FDA in the first half of 2023. SP-3164 aims to treat various cancers, building on the efficacy of previous compounds like avadomide while enhancing safety.
Salarius Pharmaceuticals (Nasdaq: SLRX) has announced a transformative acquisition of a targeted protein degradation portfolio from DeuteRx, significantly enhancing its oncology pipeline. The acquisition includes the lead candidate SP-3164 (formerly DRX-164), which is set to enter clinical trials in 2023. Salarius aims to develop this candidate and additional assets targeting previously undruggable cancer-promoting proteins. The agreement involves an upfront payment of $1.5 million and shares, with potential future payments totaling up to $188 million based on milestones.
Salarius Pharmaceuticals will present at H.C. Wainwright BioConnect and participate in Biotech Showcase and BIO Partnering @ JPM, all virtually alongside the 40th Annual Healthcare Conference 2022. Key dates include Biotech Showcase from January 10-12, H.C. Wainwright BioConnect from January 10-13, and BIO Partnering @ JPM from January 10-14. CEO David Arthur will deliver a presentation on seclidemstat, Salarius' investigational drug for pediatric and other cancers. Salarius has received FDA designations for Ewing sarcoma and aims to expand its clinical trials in cancers with high unmet needs.